Newport Beach, Calif. and Edmonton, Canada (May 22, 2025) – CureDuchenne Ventures announced an initial $1M investment in Entos Pharmaceuticals Inc (Entos), a biotech company that develops genetic medicines utilizing […]
CureDuchenne Training Therapists in China In March 2025, CureDuchenne expanded its commitment to advancing care worldwide as Doug Levine, PT, traveled to China to lead a series of professional education sessions […]
By Debra Miller, Founder and CEO of CureDuchenne Duchenne International Outreach: Bridging Gaps in Duchenne Care At CureDuchenne, we have always believed in the transformative power of connection—the kind of […]
“The Remarkable Life of Ibelin” Review by Hawken Miller, Writer and Advocate When Mats Steen, a young Norwegian man, passed away from Duchenne muscular dystrophy at 25, his parents Robert […]
By Debra Miller, Founder and CEO of CureDuchenne I’m honored to share two transformative events that embody both the resilience of the human spirit and the strength of our community: […]
Read a message from our founder and CEO The recently released award-winning Netflix documentary “The Remarkable Life of Ibelin,”* highlights the life of Mats Steen, a Norwegian World of Warcraft […]
CureDuchenne welcomes the recent initiative the Food and Drug Administration (FDA) has taken to improve efficiencies in drug development, manufacturing, and the review process for new drug applications that incorporate […]
In a promising development, the Secretary’s Advisory Committee on Heritable Disorders in Newborns and Children (ACHNDC) has advanced the nomination of Duchenne muscular dystrophy (DMD) for inclusion in the Recommended Uniform Screening Panel (RUSP), a list of disorders that are screened for at birth.
We at CureDuchenne are excited to acknowledge the recent announcement by the United States Food and Drug Administration (FDA) about the creation of the “Rare Disease Innovation Hub.” This new […]
